Background
Older transplant-ineligible mantle cell lymphoma (MCL) patients had limited frontline options beyond bendamustine-rituximab (BR). SHINE tested whether adding the BTK inhibitor ibrutinib to BR induction plus rituximab maintenance improves outcomes in patients aged ≥65 with untreated MCL.
Interventions and follow up
Arm A: Ibrutinib 560 mg PO daily + bendamustine 90 mg/m2 days 1-2 + rituximab 375 mg/m2 day 1 every 28 days x6 cycles, then rituximab maintenance + ibrutinib until progression
Arm B: Placebo + bendamustine + rituximab x6 cycles, then rituximab maintenance + placebo
Population: N=523, untreated MCL, age ≥65, transplant-ineligible
Primary endpoint: progression-free survival
Median follow-up: 84.7 months
Arm B: Placebo + bendamustine + rituximab x6 cycles, then rituximab maintenance + placebo
Population: N=523, untreated MCL, age ≥65, transplant-ineligible
Primary endpoint: progression-free survival
Median follow-up: 84.7 months
Results
Median PFS: 80.6 vs 52.9 months (HR 0.75, 95% CI 0.59–0.96, P=.01)
OS: no significant benefit (HR 1.07, 95% CI 0.81–1.40, P=.65)
Complete response: 65.5% vs 57.6% (P=.06)
Subgroups: consistent across MIPI and TP53 status
OS: no significant benefit (HR 1.07, 95% CI 0.81–1.40, P=.65)
Complete response: 65.5% vs 57.6% (P=.06)
Subgroups: consistent across MIPI and TP53 status
Adverse events
Overall: Grade 3-4 AEs 81.5% vs 77.3%; treatment discontinuation for AE higher with ibrutinib
Cardiac/bleeding: atrial fibrillation 13.9% vs 6.5%; major bleeding more frequent with ibrutinib
Infections: pneumonia 19.6% vs 17.3%
Other: rash and arthralgia more common with ibrutinib; on-treatment deaths 10.7% vs 6.1%
Cardiac/bleeding: atrial fibrillation 13.9% vs 6.5%; major bleeding more frequent with ibrutinib
Infections: pneumonia 19.6% vs 17.3%
Other: rash and arthralgia more common with ibrutinib; on-treatment deaths 10.7% vs 6.1%
Conclusions
Adding ibrutinib to BR prolonged PFS by ~28 months in older untreated MCL, but without OS benefit and with substantially higher toxicity (atrial fibrillation, bleeding, infections). Risk-benefit requires careful patient selection.
Key Limitations
No OS benefit despite PFS gain; higher toxicity and treatment-related deaths; continuous ibrutinib until progression adds cost and cumulative toxicity; superseded by safer covalent/non-covalent BTKis (acalabrutinib, zanubrutinib) not tested here; TP53-mutated subset still poor.
Clinical Context
Although SHINE met its primary endpoint, the absence of OS benefit and ibrutinib's later voluntary US market withdrawal for MCL limited frontline uptake. ESMO/ASCO guidance favors safer second-generation BTK inhibitors; the subsequent ECHO trial (acalabrutinib-BR) extended this approach with a better tolerability profile.